BridgeBio Pharma, Inc.BBIONASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank90
3Y CAGR+16.1%
5Y CAGR+12.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+16.1%/yr
vs +4.7%/yr prior
5Y CAGR
+12.5%/yr
Recent acceleration
Acceleration
+11.4pp
Accelerating
Percentile
P90
Near historical high
vs 5Y Ago
1.8x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 48.51% |
| Q3 2025 | -35.81% |
| Q2 2025 | 59.50% |
| Q1 2025 | -2.00% |
| Q4 2024 | -8.17% |
| Q3 2024 | -341.71% |
| Q2 2024 | 134.03% |
| Q1 2024 | -75.88% |
| Q4 2023 | 14.05% |
| Q3 2023 | -28.12% |
| Q2 2023 | 21.46% |
| Q1 2023 | -54.78% |
| Q4 2022 | 31.01% |
| Q3 2022 | -343.84% |
| Q2 2022 | 81.04% |
| Q1 2022 | -19.97% |
| Q4 2021 | -10.15% |
| Q3 2021 | -32.55% |
| Q2 2021 | 39.17% |
| Q1 2021 | -56.62% |
| Q4 2020 | 26.90% |
| Q3 2020 | -49.90% |
| Q2 2020 | -4.68% |
| Q1 2020 | -10.13% |
| Q4 2019 | -52.42% |
| Q3 2019 | 26.74% |
| Q2 2019 | -15.40% |
| Q1 2019 | -27.42% |
| Q4 2018 | -21.12% |
| Q3 2018 | -12.86% |
| Q2 2018 | -89.16% |
| Q1 2018 | 0.00% |